We are live on
!
Find out more
NCM
NEXTBio Capital Management Portfolio holdings
AUM
$217M
This Fund
S&P 500
This Quarter
Est. Return
+26.16%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$217M
AUM Growth
+$2.03M
(+0.94%)
Cap. Flow
-$26.9M
Cap. Flow
% of AUM
-12.39%
Top 10 Holdings %
Top 10 Hldgs %
77.7%
Holding
27
New
3
Increased
7
Reduced
5
Closed
5
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Structure Therapeutics
GPCR
|
+$7.93M |
| 2 |
Shattuck Labs
STTK
|
+$3.6M |
| 3 |
Pharvaris
PHVS
|
+$3.27M |
| 4 |
IVA
Inventiva
IVA
|
+$2.18M |
| 5 |
LBRX
LB Pharmaceuticals
LBRX
|
+$2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
TERN
Terns Pharmaceuticals
TERN
|
+$31.9M |
| 2 |
Compass Therapeutics
CMPX
|
+$4.49M |
| 3 |
Oculis Holding
OCS
|
+$3.98M |
| 4 |
KALV
KalVista Pharmaceuticals
KALV
|
+$2.65M |
| 5 |
CMPS
Compass Pathways
CMPS
|
+$2.49M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Protagonist Therapeutics
PTGX
$9.34B
| $26.9M | 12.37% |
219,333
-10,286
| -4% | -$1.07M |
|
|
2
Shattuck Labs
STTK
$707M
| $25.9M | 11.9% |
3,727,348
+577,441
| +18% | +$3.6M |
|
|
CMPS
3
Compass Pathways
CMPS
$1.9B
| $25.1M | 11.56% |
1,775,759
-245,648
| -12% | -$2.49M |
|
|
4
Structure Therapeutics
GPCR
$3.38B
| $16.8M | 7.71% |
312,496
+179,257
| +135% | +$7.93M |
|
5
Vor Biopharma
VOR
$1.34B
| $16.4M | 7.53% |
889,164
-110,803
| -11% | -$1.68M |
|
6
Rhythm Pharmaceuticals
RYTM
$7.38B
| $14.6M | 6.73% |
131,758
+5,680
| +5% | +$514K |
|
|
PVLA
7
Palvella Therapeutics
PVLA
$2.16B
| $13.7M | 6.32% |
89,909
+7,223
| +9% | +$877K |
|
8
Xenon Pharmaceuticals
XENE
$5.81B
| $11.1M | 5.09% |
183,225
| – | – |
|
|
ZBIO
9
Zenas BioPharma
ZBIO
$2.04B
| $10.8M | 4.98% |
426,736
| – | – |
|
10
Oric Pharmaceuticals
ORIC
$1.37B
| $7.65M | 3.52% |
706,124
+182,505
| +35% | +$1.65M |
|
|
IVA
11
Inventiva
IVA
$1.11B
| $6.76M | 3.11% |
1,787,984
+454,500
| +34% | +$2.18M |
|
|
CBIO
12
Crescent Biopharma
CBIO
$659M
| $6.71M | 3.09% |
372,856
| – | – |
|
13
Vaxcyte
PCVX
$8.9B
| $6.23M | 2.87% |
107,223
+12,000
| +13% | +$652K |
|
14
Cogent Biosciences
COGT
$6.02B
| $5.07M | 2.33% |
131,075
-113
| -0.1% | -$3.95K |
|
15
Verastem
VSTM
$654M
| $4.99M | 2.3% |
1,306,800
| – | – |
|
16
Disc Medicine
IRON
$3.07B
| $3.85M | 1.77% |
52,655
| – | – |
|
|
17
Pharvaris
PHVS
$2.48B
| $3.74M | 1.72% |
+108,055
| New | +$3.27M |
|
18
Zai Lab
ZLAB
$2.93B
| $3.48M | 1.6% |
183,362
| – | – |
|
|
BIOA
19
BioAge Labs
BIOA
$443M
| $2.47M | 1.14% |
+100,732
| New | +$1.82M |
|
|
LBRX
20
LB Pharmaceuticals
LBRX
$1.54B
| $2.22M | 1.02% |
+68,249
| New | +$2M |
|
|
EVMN
21
Evommune Inc
EVMN
$480M
| $1.58M | 0.73% |
119,063
-65,000
| -35% | -$1.51M |
|
22
Adicet Bio
ACET
$84.8M
| $1.36M | 0.63% |
157,827
| – | – |
|
|
23
Compass Therapeutics
CMPX
$432M
| – | – |
-848,204
| Closed | -$4.49M |
|
|
KALV
24
DELISTED
KalVista Pharmaceuticals
KALV
| – | – |
-131,796
| Closed | -$2.65M |
|
|
25
Oculis Holding
OCS
$678M
| – | – |
-149,592
| Closed | -$3.98M |
|
Similar funds
HIMS
CWM
PP
WWM
CA
ECM
RFM
DCM
NEXTBio Capital Management's Q2 2026 Portfolio in Review
As of Q2 2026, NEXTBio Capital Management held 27 positions worth $217M, up 0.94% from $215M the previous quarter. Its ten largest holdings account for 78% of the portfolio.
NEXTBio Capital Management withdrew a net $26.9M in Q2 2026, closing 5 positions and reducing 5 holdings. Its most notable exit was Terns Pharmaceuticals, an estimated $31.9M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
Against the trend, NEXTBio Capital Management opened a new position in Pharvaris worth $3.74M.
- NEXTBio Capital Management's largest Q2 2026 buy was Pharvaris: 108,055 shares worth $3.74M.
- NEXTBio Capital Management added most to Structure Therapeutics in Q2 2026, an estimated $7.93M increase.
- NEXTBio Capital Management's biggest Q2 2026 reduction was Compass Pathways, cutting an estimated $2.49M.
- NEXTBio Capital Management fully exited Terns Pharmaceuticals in Q2 2026, selling an estimated $31.9M.
- NEXTBio Capital Management's ten largest holdings make up 78% of its $217M portfolio in Q2 2026.
- NEXTBio Capital Management opened 3 new positions and closed 5 in Q2 2026.
- NEXTBio Capital Management's portfolio value rose 0.94% quarter-over-quarter to $217M.
Based on NEXTBio Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.